A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Integrative Genomic Profiling of Human Prostate Cancer

Barry S. Taylor, Nikolaus Schultz, Haley Hieronymus et al. · Cancer Cell · 2010 · 3.8K citations · Full text

Medicine, Genetics, Oncology +14

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

Howard I. Scher, Susan Halabi, Ian F. Tannock et al. · Journal of Clinical Oncology · 2008 · 2.2K citations · Full text

Medicine, Oncology, Urology +17

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

Donavan T. Cheng, Talia Mitchell, Ahmet Zehir et al. · Journal of Molecular Diagnostics · 2015 · 2.2K citations · Full text

Medicine, Molecular Biology, Oncology +14

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

Carson C. Thoreen, Seong A. Kang, Jae Won Chang et al. · Journal of Biological Chemistry · 2009 · 1.8K citations · Full text

Life Sciences, Oncology, Pharmacology +14